Volume 13, Number 7—July 2007
Research
Antimicrobial Drugs and Community-acquired Methicillin-Resistant Staphylococcus aureus, United Kingdom
Verena Schneider-Lindner*†, J. A. Delaney*†, Sandra Dial†‡, Andre Dascal‡, and Samy Suissa*†
Table 4
Sensitivity analysis for the clinical code used to define methicillin-resistant Staphylococcus aureus (MRSA)*
| Clinical code† | Case-patients |
Control-patients |
Crude OR | Adjusted OR‡ | 95% CI | ||
|---|---|---|---|---|---|---|---|
| N (%) | % Exposed | N | % Exposed | ||||
| Any code | 1,981 (100) | 61.1 | 19,779 | 35.2 | 2.98 | 2.61 | 2.36–2.89 |
| 4JP..00 | 1,735 (85.5) | 62.2 | 17,327 | 35.7 | 3.05 | 2.66 | 2.39–2.97 |
| SP25800 | 157 (8.8) | 60.5 | 1,570 | 32.7 | 3.34 | 2.99 | 2.06–4.33 |
| ZV02A00 | 113 (5.7) | 47.8 | 1,122 | 30.5 | 2.09 | 1.98 | 1.30–3.01 |
*Risk for MRSA diagnosed in the community for persons with any number of antimicrobial drug prescriptions (exposed) in the 30–365 days before their index date relative to risk for MRSA for persons with no prescriptions during the same period. Data from 4 different analyses of a matched case-control study of patients listed in the General Practice Research Database, UK, 2000–2004. OR, odds ratio; CI, confidence interval.
†4JP..00, MRSA positive; SP25800, MRSA infection of postoperative wound; ZV02A00, [V]MRSA multiple-resistant Staphylococcus aureus infection carrier.
‡Adjusted for all covariates in Table 1.
Page created: June 21, 2010
Page updated: June 21, 2010
Page reviewed: June 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.